Special Issue "Gastric Cancers: Molecular Mechanisms, Novel Targets and Immunotherapies: From Bench to Clinical Therapeutics"
Deadline for manuscript submissions: 28 February 2024 | Viewed by 4678
Interests: gastroesophageal cancer; cancer stem cells; immunotherapy; tumor microenvironment; peritoneal metastases
Interests: gastroesophageal cancer; peritoneal carcinoma of GI origin; clinical trials; multidisciplinary care; multimodality therapy
We are pleased to announce a Special Issue in MDPI Cancers (5-Year Impact
Factor: 6.886 (2021)) focusing on gastric cancers (GC). This Special Issue welcomes a broad spectrum of research, from very basic molecular biology to translational research, covering novel techniques/methods, novel onco-targets, and novel targets on tumor microenvironments, including tumor-associated macrophages (TAM), cancer-associated fibroblasts (CAFs), as well as immunosuppressive myeloid cells that potentially translate into clinics. This Special Issue aims to cover multiple facets, from multidisciplinary research to clinical applications.
Novel techniques such as CRISPR-based genome-wide screening, de novo targets of genes and splice variants, new ideas and methodologies, and novel targets in TME, including CAFs and macrophages, are welcome. Immunotherapy has offered a great therapeutic potential for GC patients as well as in a broad spectrum of other cancers; however, further research is needed in novel immuno-target therapy. Crosstalk among tumor cells, immune cells, and stroma signaling may promise more positive therapeutic targets. New ideas and methodologies may open a new world for researchers to better understand neoplasm, oncogenesis, and metastasis.
We invite the submission of great works from basic scientists, basic/clinical researchers involved in translational studies, and clinicians.
We welcome original research papers and reviews focusing on gastric cancer. Research areas may include but are not limited to the following:
- Discovery of new targets of gene, splice variants, RNAs;
- Cancer/stroma, immune cells crosstalk, tumor microenvironment;
- Immune biomarker and immunotherapy;
- New therapeutic modality and clinical trials;
- RNAseq, WES, exosomes, proteomics, organoids;
- Epigenomics, spatial transcriptomics.
We look forward to receiving your contributions.
Prof. Dr. Shumei Song
Prof. Dr. Jaffer A. Ajani
Dr. Jiankang Jin
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- novel oncogene targets
- interplays among cancer, stroma, immune cells
- tumor microenvironment (TME)
- immune biomarker
- new therapeutic modality
- translational research
- clinical trials